GW Pharmaceuticals Meets Q4 Revenue Guidance but Losses No Bueno Scott Willis·February 25, 2020Once a promising biotech stock, but now out of favor. Were 4th quarter results enough to turn this...Investing·1 Comment·
Marijuana Investor Roundup: Analysis of the Week’s Most Important Events (Jan 18th, 2020) Scott Willis·January 18, 2020A weekly review of only the most important cannabis news to impact your portfolioMarijuana News·1 Comment·
GW Pharmaceuticals Releases a Q4 Revenue Beat, but Will the Rapid Growth Continue? Scott Willis·January 13, 2020GW Pharmaceuticals' (NASDAQ: GWPH) 7% revenue beat was cheered by the markets, but with revenue growth slowing can...Marijuana News·0 Comments·
EU Approves Epidyolex to Treat Severe Epilepsy in Children Martin Green·September 23, 2019The EU has broken new ground by approving Epidyolex in order to help doctors across Europe treat children...Marijuana Politics·0 Comments·
Earnings Update: Second GW Pharmaceuticals Stock Price Increase After February’s Alzheimer’s Trial News Martin Green·February 15, 2019GW Pharmaceuticals (GWPH) saw its share price increase again after releasing earnings, this followed a February spike after...Marijuana News·0 Comments·
Epidiolex Maker GW Pharmaceuticals Raises $345 Million Through Share Sale Martin Green·October 10, 2018GW Pharmaceuticals (NASDAQ: GWPH), maker of the epilepsy treatment Epidiolex, has raised $345 million to fund an expansion...Marijuana News·1 Comment·
Investing in Medical Marijuana Stocks – Quantifying the Upside Scott Willis·June 15, 2018Epilepsy treatment is a $6 billion opportunity for the Marijuana industry. This report explores how to invest in...Marijuana Analysis·14 Comments·
